Heartflow, Inc. income statement HTFL

In fiscal 2025, which ended Dec 31, 2025, Heartflow, Inc. reported revenue of $176.0 million. It recorded a net loss of $116.8 million. The operating loss came to $64.1 million, an operating margin of -36.4%. Diluted earnings per share were -$3.17. Over the twelve months ended Jun 30, 2026, revenue was $212.1 million and the net loss was $118.4 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Revenue
212
176
Cost of revenue
42
41
Gross profit
170
135
Research and development
84
65
Selling, general and administrative
159
134
Operating expenses
—
199
Operating income
-80
-64
Other non-operating income (expense)
-1
-0
Other income (expense)
—
-53
Pretax income
-118
-117
Income tax
-0
-0
Net income
-118
-117
Basic EPS
-1.55
-3.17
Diluted EPS
-1.55
-3.17
Weighted average shares, basic
76
37
Weighted average shares, diluted
76
37
Other measures
Depreciation and amortization
5
5
EBITDA
-75
-59
Interest coverage
-23.18x
-4.22x
Margins
Gross margin
80.08%
76.80%
Operating margin
-37.84%
-36.39%
Pretax margin
-55.86%
-66.39%
Profit margin
-55.82%
-66.35%
EBITDA margin
-35.34%
-33.30%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
HTFL (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Francisco, CA
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1464521
Former names
Cardiovascular Simulation, Inc. (until Jun 14, 2010)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.